echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Gynaecological malignant tumor patients aging, "red house technology" to protect life and son.

    Gynaecological malignant tumor patients aging, "red house technology" to protect life and son.

    • Last Update: 2020-08-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    (Health Times network end of the reporter Wei Wei in Fudan University affiliated obstetrics and gynecology hospital Shen Yan)
    . Statistics from the Shanghai Center for Disease Control and Prevention show that endometrial cancer has become the first gynaecological tumor in Shanghai, and shows a trend of aging, especially in 20-44 years of women in the fertility age group, the incidence of endometrial cancer in 7%. Women of the right age who have a reproductive need face the dilemma of life-saving or having children because of malignant tumors.
    recently, the three-day 2019 Red House Forum and the 5th Fudan University Affiliated Obstetrics and Gynaecology Hospital International Obstetrics and Gynecology Summit Forum, more than 300 domestic and foreign obstetrics and gynecology experts gathered together, including endometrial cancer, including a number of the latest research results of the "Red House technology" has become a new trend in the industry.
    's team of Professor Waukerin completed the world's first extensive excision of a mid-pregnancy laparoscopic eccaramy in 2013, marking a new milestone in cervical cancer surgery during pregnancy. Faced with the trend of the increasingly young age of cervical cancer, Professor Hua fully respects women's willingness to reproduce for the vast number of patients of childbearing age to achieve the greatest possibility of fertility. At present, more than 800 cases of cervical cancer retention fertility surgery have been completed, including more than 200 patients with reproductive needs, more than 80 have completed childbirth.
    , Professor Chen Xiaojun of Honghouse Hospital and her leading multidisciplinary team of endometrial lesions in China, on the basis of many years of practice, gradually explore a way to solve the problem through standardized diagnosis and treatment, integrated management. Professor Chen Xiaojun told reporters that the number of team outpatient clinics increased year by year, 2013-2018 membrane cancer and precancerous lesions care treatment 622 times, the effective mitigation rate of 95.7-97.4%, higher than the literature reported 70%-80%, in the hospital reproductive center assisted treatment patient pregnancy rate of 53.8%, also higher than the literature reported 30%-40%.
    compared with cervical cancer and endometrial cancer, the incidence of ovarian tumors in adolescence is lower than that of adults, but tends to be more malignant, and there is a tendency to increase the incidence in recent years. In 2018, Dr. Sun Hong, chief gynaecologist at Red House Obstetrics and Gynaecology Hospital, successfully operated on a 16-year-old schoolgirl suffering from ophthalmaas, a malignant tumor of reproductive cell origin, and kept her ovaries in place to keep her hopes for future fertility.
    However, these medical experts caution that childcare treatment must meet certain conditions. "Not all cervical cancers can be treated with care, and factors such as type of tumor, age of the patient, and stage of the tumor are important indicators that affect the care of malignant tumors and must be fully assessed by doctors."
    Although Professor Wauke-Chin's team has developed a mature model of cervical cancer care, she still places a strong emphasis on care: when the lesions are less than 2 cm and the vasculature is soaked and lymphatic metastasis, and the tumor is in its early stages, it can be considered for care treatment. For patients with high degree of malignancy and poor prognosis, such as endocrine adenocarcinoma with small cells, patients with small cells are not advised to provide care for treatment, regardless of the stage of tumor development. "
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.